Frazier Life Sciences Public Fund, L.P. - 30 Jun 2025 SCHEDULE 13G/A Report for Maze Therapeutics, Inc. Common Stock - par value $0.001 per share (MAZE)

Filing Manager
Frazier Life Sciences Public Fund, L.P.
Reporting Manager
Frazier Life Sciences Public Fund, L.P.
Security
Maze Therapeutics, Inc. Common Stock - par value $0.001 per share
Symbol
MAZE
Shares outstanding
43,544,351 shares
Disclosed Ownership
3,352,915 shares
Ownership
7.7%
Form type
SCHEDULE 13G/A
Filing time
14 Aug 2025, 13:43:15 UTC
Date of event
30 Jun 2025
Previous filing
29 Apr 2025
Next filing
13 Feb 2026
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Frazier Life Sciences Public Fund, L.P. disclosed 7.7% ownership in Maze Therapeutics, Inc. Common Stock - par value $0.001 per share (MAZE) on 30 Jun 2025."

Quick Takeaways

  • Frazier Life Sciences Public Fund, L.P. filed SCHEDULE 13G/A for Maze Therapeutics, Inc. Common Stock - par value $0.001 per share (MAZE).
  • Disclosed ownership: 7.7%.
  • Date of event: 30 Jun 2025.

What Changed

  • Previous schedule filing date: 29 Apr 2025.
  • Current filing was accepted on 14 Aug 2025, 13:43.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Official SEC Source

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (17)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Frazier Life Sciences Public Fund, L.P. 7.7% 3,352,915 0 3,352,915 /s/ Steve R. Bailey By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.
FHMLSP, L.P. 7.7% 3,352,915 0 3,352,915 /s/ Steve R. Bailey By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.
FHMLSP, L.L.C. 7.7% 3,352,915 0 3,352,915 /s/ Steve R. Bailey By Steve R. Bailey, CFO of FHMLSP, L.L.C.
Frazier Life Sciences Public Overage Fund, L.P. 2.3% 989,351 0 989,351 /s/ Steve R. Bailey By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P., GP of Frazier Life Sciences Public Overage Fund, L.P.
FHMLSP Overage, L.P. 2.3% 989,351 0 989,351 /s/ Steve R. Bailey By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P.
FHMLSP Overage, L.L.C. 2.3% 989,351 0 989,351 /s/ Steve R. Bailey By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C.
Frazier Life Sciences X, L.P. 0.2% 75,982 0 75,982 /s/ Steve R. Bailey By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.
FHMLS X, L.P. 0.2% 75,982 0 75,982 /s/ Steve R. Bailey By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.
FHMLS X, L.L.C. 0.2% 75,982 0 75,982 /s/ Steve R. Bailey By Steve R. Bailey, CFO of FHMLS X, L.L.C.
Frazier Life Sciences XI, L.P. 0.3% 149,026 0 149,026 /s/ Steve R. Bailey By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.
FHMLS XI, L.P. 0.3% 149,026 0 149,026 /s/ Steve R. Bailey By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.
FHMLS XI, L.L.C. 0.3% 149,026 0 149,026 /s/ Steve R. Bailey By Steve R. Bailey, CFO of FHMLS XI, L.L.C.
James N. Topper 0.2% 75,982 0 75,982 /s/ Steve R. Bailey By Steve R. Bailey, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017
Patrick J. Heron 0.2% 75,982 0 75,982 /s/ Steve R. Bailey By Steve R. Bailey, Attorney-in-Fact for Patrick J. Heron, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017
Albert Cha 0% 0 0 0 /s/ Steve R. Bailey By Steve R. Bailey, Attorney-in-Fact for Albert Cha, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021
James Brush 0% 0 0 0 /s/ Steve R. Bailey By Steve R. Bailey, Attorney-in-Fact for James Brush, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021
Daniel Estes 0% 0 0 0 /s/ Steve R. Bailey By Steve R. Bailey, Attorney-in-Fact for Daniel Estes, pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022

Sponsored